The impact of pharmacotherapy on weight management in type 2 diabetes

International Journal of Obesity

Volumn 23, Issue , 1999, Pages S12-S17

  Hauner, Hans ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Obesity; Pharmacotherapy; Type 2 diabetes; Weight management

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLUCOSE; INSULIN; METFORMIN; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

BODY FAT; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; OBESITY; PRIORITY JOURNAL; RISK FACTOR; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; WEIGHT LOSS;

EID: 0032772848     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800956     Document Type: Article

References (44)

1. Polonsky KS, Sturis J, Bell GL. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
2. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
3. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
4. Hauner H, Beelte S, Haastert B. Diagnosestellung und Ersttherapie bei Typ-ll-Diabetes. Ergebnisse einer standardisierten Patientenbefragung. 1. Diagnosestellung bei Typ-ll-Diabeti- kem. Diab Stoffw 1995; 4: 402-406.
5. Eckel RH. Insulin resistance: an adaptation for weight maintenance. Lancet 1992; 340: 1452-1453.
6. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761-811.
7. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor-a: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
8. Hauner H, Petruschke T, Russ M, Röhrig K, Eckel J. Effects of tumour necrosis factor-alpha (TNF) on glucose transport and lipid metabolism of newly differentiated human fat cells in culture. Diabetologia 1995; 38: 764 - 771.
9. Hamann A, Matthaei S. Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996; 104: 293 - 300.
10. European NIDDM Policy Group. A Desktop Guide for the Management of Non-insulin-dependent Diabetes Mellitus. 2nd edn. Mainz: Kirchheim Verlag, 1993.
11. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-175.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment of risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
14. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
15. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721 - 749.
16. DeFronzo RA, Goodman AM and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non- insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-549.
17. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-1880.
18. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (Bay g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non- insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-451.
19. Wolever TMS, Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin- dependent diabetes. Int J Obes 1997; 21: 756 - 763.
20. Livesey G. The energy values of dietary fibre and sugar alcohols for man. Nutr Res Rev 1992; 5: 61 - 84.
21. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 11 diabetes. Diabetes 1996; 45: 1661-1669.
22. Spiegelman BM. PPAR: adipogénie regulator and thiazolidi- nedione receptor. Diabetes 1998; 47: 515 - 522.
23. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp Clin Endocrinol Diabetes 1997; 105: 187-195.
24. US Department of Health and Human Services. Cardiac valvulopathy associated with exposure to fenfluramine and dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997. Morbidity and Mortality Weekly Report 1997; 46: 1061-1066.
25. Scheen AJ, Lefebvre PJ. Pharmacological treatment of the obese diabetic patient. Diabetes Metab 1993; 19: 547-559.
26. Dykes RJW. The effect of low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics. Postgrad Med J 1973; 49: 318-324.
27. Salmela PI, Sotaniemi EA, Viikari J, Solakivi-Jaakkola T, Järvensitu P. Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins and antipyrine metabolism. Diabetes Care 1981;4:535-540.
28. Verdy M, Charbonneau L, Verdy I, Belanger R, Boite E, Chiasson J-L. Fenfluramine in the treatment of non-insulin- dependent diabetics: hypoglycemic vs. anorectic effect. Int J Obes 1983; 7: 289-297.
29. McTavish H, Heel RC. Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obe-sity. Drugs 1992; 43: 713-733.
30. Proietto J, Thorbum AW, Fabris S, Harrison LC. Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994; 23: 127-134.
31. Willey KA, Molynaux LM, Overland JE, Yue DK. The effect of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med 1992; 9: 341-343.
32. Marks SJ, Moore NR, Clark ML, Strauss BJG, Hockaday TDR. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 1996; 4: 1-7.
33. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992; 55 (Suppl): 181S-184S.
34. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes 1997; 21 (Suppl 1): S30-S36.
35. Griffiths J, Brynes AE, Frost G, Bloom SR, Finer N, Jones SP, Romanee FM. Sibutramine in the treatment of overweight non-insulin-dependent diabetics. Int J Obes 1995; 19 (Suppl 2): S41.
36. Pierce NS, Stubbs TA, Macdonald I A, Tattersall RB. The effect of sibutramine and weight reduction on insulin sensitivity in obese type 2 diabetics. Int J Obes 1998; 22 (Suppl 3): S669.
37. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 (Suppl 3): S12-S23.
38. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M for the European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
39. Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-1294.
40. Mitchell TH, Ellis RDM, Smith SA, Robb G, Cawthome MA. Effects of BRL 35135, a -adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. Int J Obes 1989; 13: 757 - 766.
41. Arch JRS, Wilson S. Prospects for ?3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 1996; 20: 191-200.
42. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
43. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kush- ner R, Hunt T, Lubina J, Patane J, Self B, McCamish M. Weight and body composition changes in lean and obese subjects treated with recombinant methionyl human leptin (rL). 8th International Congress on Obesity, Hot Topic Poster, 1998.
44. Hauner H, Tilenius H, Haastert B, von Ferber L. Quality of care of diabetic patients in the primary health care system.Diab Stoffw 1997; 6: 139-144.